Clinical Trials Logo

Clinical Trial Summary

The study addresses the hypothesis that a gradual build-up in arterial resistance and microvascular endothelial dysfunction due to common comorbidities such as hypertension and diabetes mellitus, on top of age related vascular and cardiac changes (mainly fibrosis and hypertrophy), is responsible for HFpEF. The HFpEF syndrome is commonly seen in elderly subjects (often females) with hypertension and diabetes.

The investigators will investigate the vascular function, cardiovascular performance and myocardial fibrosis in different cohorts of subjects to try and prove this hypothesis. There will be 5 groups of subjects, all ≥ 70 years of age, as follows:

A) Normal healthy volunteers without major comorbidities including hypertension or diabetes B) Patients with hypertension only (without diabetes mellitus) C) Patients with hypertension AND diabetes mellitus D) Patients with HFpEF. E) A parallel group of patients with Heart Failure with reduced Ejection Fraction (HFrEF) group.

Arterial resistance measured by pulse wave velocity will be the primary measure and will be compared between groups A to D. A separate comparison will be made between groups D and E. Other secondary measures will focus on endothelial function (Laser Doppler measurements) and other cardiovascular performance measures (peak VO2 by CPEX, 6-minute walk distance). Bloods samples will be taken for NT-proBNP, high sensitivity Troponin T, Galectin 3 and also stored for testing later for vascular biomarkers.

Clinical Trial Description

The study will be a pathophysiological, single-centre, observational study, in which all 4 groups, including the parallel-group will be investigated in terms of qualitative-, echocardiographic-, arterial resistance, exercise testing (CPEX and 6-MWT), endothelial dysfunction assessment by Laser Doppler and vascular biomarker measurements. We intend to investigate if there is increasing arterial resistance from group "A" to group "D" and a significant difference in arterial resistance between groups "D" and "E" by measuring the PWV.

Primary Outcome Our primary outcome will be a difference in arterial resistance between the groups and the parallel group, as measured by aortic PWV.

Secondary Outcomes

The secondary outcomes are to assess and compare endothelial function and cardiovascular performance in all groups as measured by the following:

- Blood tests: NTproBNP, Galectin-3

- Urinalysis: Albumin, Creatinine and Metabolite profiles ("metabolomics"), related to cardiovascular risk and insulin resistance

- Transthoracic echocardiography (TTE) indices of LV diastolic function, tissue Doppler imaging and strain rate imaging

- Exercise tolerance: 6-minute walk test and a Cardiopulmonary Exercise Test (CPEX)

- Microvascular function: Laser Doppler ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03186833
Study type Observational
Source University Hospitals Coventry and Warwickshire NHS Trust
Contact Danish Ali, MB ChB, MRCP
Phone +442476964000
Status Recruiting
Phase N/A
Start date June 6, 2017
Completion date April 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03251183 - Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF N/A
Active, not recruiting NCT02459626 - Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT02173548 - Interleukin-1 Blockade in HF With Preserved EF Phase 2
Recruiting NCT03310099 - Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients N/A
Completed NCT02638961 - Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF N/A
Not yet recruiting NCT03184311 - High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction N/A
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States N/A
Recruiting NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Phase 2
Recruiting NCT03289481 - Treatment of HFpEF With Nitrate Supplement N/A
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Terminated NCT03195660 - Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study N/A
Recruiting NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea N/A
Not yet recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Recruiting NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure N/A
Recruiting NCT02923609 - Cell Therapy in HFpEF Phase 2
Completed NCT01919177 - Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise Capacity Phase 2
Recruiting NCT03465072 - Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT03269630 - New Orleans Pulmonary Hypertension Biobank N/A
Recruiting NCT03327649 - Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction N/A
Not yet recruiting NCT03541603 - Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Phase 2